{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"Should Competitors of Negotiated Drugs Review Their Market Strategies? | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"3gCeR9smXe\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/should-competitors-of-negotiated-drugs-review-their-market-strategies\">Should Competitors of Negotiated Drugs Review Their Market Strategies?<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/should-competitors-of-negotiated-drugs-review-their-market-strategies\/embed#?secret=3gCeR9smXe\" width=\"600\" height=\"338\" title=\"&#8220;Should Competitors of Negotiated Drugs Review Their Market Strategies?&#8221; &#8212; Avalere Health Advisory\" data-secret=\"3gCeR9smXe\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2022\/04\/25732-1-Jordan_Banks-400x600-1.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"[vc_row][vc_column][vc_column_text]The Inflation Reduction Act (IRA) is bringing landmark policy changes\u00a0to the healthcare industry, raising important questions about\u00a0pipeline investment,\u00a0drug price negotiation, and reimbursement. In the IRA Question of the Week series, Avalere answers the pressing questions shaping healthcare stakeholders\u2019 strategic decision-making as the law is implemented. In the second part of this two-part installment, Avalere experts&hellip;"}